INTRODUCTION
Data consisting of repeated measurements taken on each of a number of individuals arise in areas such as assay development, pharmacokinetics, and studies of growth and decay.
Here, the term "individual" may refer to experiments, subjects, plants, laboratories, devices, etc., and repeated measurements on an individual may be taken over time, dose, or some other set of conditions. The relationship between response, y, and the repeated covariate, x, is often nonlinear in its parameters. For example, assay data frequently conform to the four-parameter logistic model (1) where x IS dose. Single-dose drug kinetics are commonly characterized by polyexponential functions based on compartment models, for example,
where x is time. A common feature in both of these contexts is a heterogeneous pattern of variability for measurements within an individual (assay run, subject) which is systematically related to overall response level.
The goals of an analysis will vary depending on the area of application. For example:
• In assay analysis, once assay procedures have stabilized, the main objective is calibration of unknown samples for the current run. Data from each run in the senes contain information on the nature of intra-assay variability. Since accurate .-2 characterization of the pattern of intra-assay variation is crucial for appropriate calibration inference, this is an important objective in the analysis of assay data.
• In pharmacokinetic studies, repeated plasma concentration measurements are collected from subjects following single or multiple dosing. In pilot experiments on volunteers, several measurements are collected from each subject, and these are used to establish an appropriate kinetic model, obtain preliminary information on values of the pharmacokinetic parameters, and assess intra-subject measurement error, such as that due to the assay used to process blood samples. Investigation of kinetics in a more extensive patient population relies on clinical data, and only a small number of measurements are usually available from each subject. Interest in this setting focuses on estimation of "typical" values for the pharmacokinetic parameters, their relationship to individual attributes such as weight or age, and the variation in the patient population. This information may be used subsequently in the adjustment of individual dosage schedules.
In both of these settings, a goal of the analysis is to characterize inter-and intraindividual variation. Analysis should be conducted in a setting which recognizes the existence of these two sources of variation in repeated measurement data and allows them to be evaluated. A natural parametric framework which accommodates these features is the nonlinear mixed effects model. In this tutorial, we discuss this model and
show how it provides a basis for inference in several application settings. In Section 2
we introduce three examples from the fields of assay development, water transport kinetics, and pharmacokinetics. Section 3 describes the model framework. An overview of approaches to estimation and inference is provided in Section 4, and some of these techniques are illustrated by application to the examples in Section 5. Table 1 shows dose-response data obtained for standard concentrations in nine runs of a bioassay for the therapeutic protein relaxin [1] . The assay is based on increased generation and release of intracellular cAMP by normal human uterine endometrial cells in the presence of relaxin. For each of the nine runs, triplicate cAMP measurements were determined by RIA for each of seven known relaxin concentrations. A single control measurement was also available for each plate. (1) is a reasonable representation of dose-response for a given run; however, parameters such as logED50 (/33), background (/32), and mean response at infinite dose (/31) vary from run to run. Variability in measured cAMP levels increases with response level for a given run (see [2] ) in a way that is similar across runs.
EXAMPLES

Bioassay of relaxin by RIA
The objective of an analysis is calibration of unknowns for the most recent run. As described in [3] and [4] , accuracy of calibration confidence intervals and precision profiles for a run will depend critically on how one characterizes this increasing intraassay variation. In Section 5, we will show how using the nonlinear mixed effects model as a framework for analysis allows this variation to be characterized using data from all nine runs, resulting in improved calibration inference.
Water transport kinetics of high flux hemodialyzers
In [5] , data are presented from an experiment to evaluate the water transport kinetics of high flux membrane dialyzers used for hemodialysis for patients with end-stage renal disease. Twenty dialyzers were evaluated in vitro with bovine blood at two different blood flow rates, 200 or 300 ml/min. For each of seven values of transmembrane pressure (mmHg) exerted on the dialyzer membrane, ultrafiltration rate (ml/hr) at which water is removed was measured for each dialyzer. These data are given in Table   2 , and profiles for each dialyzer are plotted in Figure 2 .
Since the relationship is governed by protein polarization, which causes a relatively constant ultrafiltration rate at high pressure, and oncotic pressure, a nonlinear model for the relationship between ultrafiltration rate and transmembrane pressure x IS appropriate [5] : (3) ..
where /31 is the maximum attainable ultrafiltration rate due to protein polarization, /3 2 is a hydraulic permeability transport rate, and /33 is the transmembrane pressure required to offset patient oncotic pressure. For a given dialyzer, the seven available observations provide enough information to fit (3) to the data for that dialyzer by nonlinear (unweighted) least squares (LS). Figure 3 shows a plot of LS residuals against predicted response, as described in [3] , for a typical dialyzer. The "fan-shaped" pattern is evidence that intra-dialyzer variability is an increasing function of ultrafiltration response level. One objective of the experiment was to contrast kinetic properties for dialyzers at the two different blood flow rates. In Section 5 we report the results of an analysis to investigate this question based on the nonlinear mixed effects model which allows .-4 incorporation of inter-and intra-dialyzer variation.
Pharmacokinetics of cefamandole
The results of a pilot study to investigate the pharmacokinetics of cefamandole, a cephalosporin antibiotic, are reported in [6] and are shown here in Table 3 . A dose of 15 mg/kg body weight of cefamandole was administered by 10 minute intravenous infusion to six healthy male volunteers, and blood samples were collected from each subject at each of fourteen time points post-dose. Plasma levels (pg/ml) for each sample were determined by HPLC. Figure 4 plots the resulting plasma level-time profiles for each subject and indicates that the biexponential function (2) arising from a twocompartment model for cefamandole kinetics is reasonable, although the values of the pharmacokinetic parameters may vary across subjects. For pharmacokinetic data, the variation associated with plasma concentrations is likely to be an increasing function of level, in part due to the nature of the HPLC assay [7, 8, 9] .
As discussed in Section 1, the goals of an analysis of data from a pilot study such as this are to characterize this intra-subject variation, which is likely to be the similar for all individuals, and to estimate the pharmacokinetic parameters. We illustrate these ideas in Section 5.
THE NONLINEAR MIXED EFFECTS MODEL
Motivation and description
In the three examples in Section 2, several common features are apparent: The same nonlinear model for the relationship between response and x is suitable for describing data for each individual, but the values of the parameters that specify the model fully may differ across individuals (inter-individual variation). Furthermore, the variability associated with response measurements for a given individual depends on response level in a way that is likely to be similar for all individuals, due to, for example, properties of an assay (intra-individual variation). Correct analysis should account for both of these features; moreover, characterization of these features may be a goal. The following nonlinear mixed effects model incorporates both sources of variation. The use of this model as an analytic tool was pioneered by Beal and Sheiner [7, 8, 9] , who recognized and advocated the need to accommodate and assess both types of variability in pharmacokinetic analysis. More general specifications than that presented here are possible, and the reader is referred to the work of Beal and Sheiner for such formulations with particular reference to pharmacokinetics.
Let Yij denote the jth response, j = 1, ... , mi' for the ith individual, i = 1, ... , n, at [3] and [9] .
With these definitions, the nonlinear mixed effects model assumes that the jth measurement on individual i can be written as (4) where fij is a random error with mean 0 and variance 1. We now turn our attention to further description of the components of the model.
Inter-individual variability
In (4), inter-individual variation is modeled through the assumption of the individualspecific regression parameter vector f3i' Part of the inter-individual variation in the values of the parameters characterizing mean response may be due to systematic dependence on individual attributes. For example, pharmacokinetic parameters are well-known to depend on an individual's weight, disease status, and so on [7, 8] .
Parameters may also vary due to unexplained random variation in the population of individuals; for example, due to natural biological variation among subjects or subtle run-to-run variation in assay procedure.
To account for these possibilities, a model for the dependence of f3 i on individual attributes and random variation may be specified. The simplest such model is that in which inter-individual variation is assumed to be entirely due to unexplained phenomena:
.
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where I is a (p xl) vector of fixed parameters and Zi is a random vector assumed to arise from a population with mean Op, a (p X 1) vector of zeros, and covariance matrix
. Equation (5) states that the f3i vary in the population of individuals about the value " their mean, and the variation in the population is described by the matrix~. The diagonal elements of~characterize the variance of each component of the f3i about " and the off-diagonal elements describe how the components vary together (covariance).
A more complicated model allows for dependence on both random and systematic phenomena. For example, in the dialyzer study of Section 2.2, water transport kinetics may be thought to vary among dialyzers in part because of flow rate and in part because of natural variation expected to occur among the devices. Both possibilities can be taken into account by assuming that f3i = 1200 + Zi if dialyzer i is used with flow rate 200 ml/min, f3i = 1300 + Zi if dialyzer i is used with flow rate 300 ml/min,
where 1200 and 1300 are (3 x 1) vectors describing the central tendency of the 3 kinetic parameters in (3) for the populations of dialyzers operated at flow rates 200 ml/min and 300 ml/min, respectively. The random component zi is again assumed to have zero mean and covariance~, so that random variation in both populations is assumed to be similar. Model (6) may be written compactly in the form of a "linear regression" model:
f3 . = W·,oy + z·
where I = [,ioo, IIoo]T, that is, the (6 x 1) vector with 1200 and 1300 stacked, and Wi is a (3 x 6) "design" matrix such that Wi = [13103, 3] (11) where h is the trivariate-valued function given in (9) and (10) . Note that because kai is assumed to be fixed, the dimensions of 1 and Zi need not be the same.
Equation (11) (5) and (7). Under such a specification, the f3i themselves are random vectors.
Intra-individual variability
In the nonlinear mixed effects model (4), intra-individual variation is modeled through the intra-individual variance function g, the parameters (j and (J, and the random errors fij. This variation is interpreted as that associated with measurements on a given individual i. It is often reasonable to assume that measurements within a given individual are statistically independent, reflected in the model by the assumption that the random errors fij are independently distributed.
In some settings, this assumption may not be realistic. When measurements are taken on a given individual at closely space time points, it is likely that successive measurements may be correlated; that is, responses taken close in time may be "more alike" than those taken far apart. This situation may be accommodated by assuming that the fij are not statistically independent but are correlated in some specifiable way.
An example is to assume that the random errors follow an autoregressive process of order 1; see [10, ch. 6]. In practice, however, it is often assumed that the fij are independent, in part because successive time points are thought to be sufficiently far apart so that such serial correlation is negligible. Another justification is that, in (4), the fact that the common (random) (3i appears in f and g will have the effect of inducing a relationship among measurements on individual i. This is considered to be adequate to account for any association that may actually exist among measurements on an individual [11] .
Based on these considerations, we assume for our discussion that the fij are independent. The methods for estimation in the nonlinear mixed effects model in Section 4 may be generalized to the case of correlated fiji see [1] for details.
Summary
For convenience, we summarize in vector notation the version of the nonlinear mixed effects model that forms the basis for our discussion. be the (mi x mi) diagonal matrix with diagonal elements gij = g{f(xij' (3i),9}. With these definitions, we write the nonlinear mixed effects model as z· '" (12) where the notation" '" (a, B)" means "distributed with mean a and covariance matrix B," M is the dimension of the random components Zi for the inter-individual regression model h, and the assumption that Zi and €i are distributed independently reflects the belief that the mechanisms governing the 2 sources of variation operate independently. This is a version of the model discussed by several authors [4, 5, 7, 8, 11, 12] .
OVERVIEW OF METHODS
Introduction
In the context of the nonlinear mixed effects model (12) , questions of interest may be formulated in terms of the components of the model. In assay analysis, for example, the objective is individual inference for a given run i; in particular, this involves estimation of f3i characterizing the standard curve for run i and estimation of 9 (which will determine the weighting scheme for this fit), calibration of unknown samples based on this estimate of f3i, and construction of calibration confidence intervals and precision profiles (which will depend on the estimates for f3i, u, and 9). In pharmacokinetic analysis, one goal is population inference; this involves determination of an appropriate function h and estimation of , and I:, all of which characterize the population of subjects. Another aim in pharmacokinetic analysis is individual inference -estimation of f3i for a particular individual. Under the model, it seems reasonable to expect that the information available from all individuals will be useful for both population and individual inference. This is in fact the case -estimates of f3i and 9, for example, that make use of information from all subjects are preferred to those based on data from individual i alone [4] .
The model (12) acknowledges that inter-and intra-individual variation should be considered in an analysis of repeated measurement data. As pointed out by Beal and Sheiner [7] , early attempts at analysis of these data did not take both features into account. In particular, the popular method of analysis was essentially to assume that the model for yij is (13) where 13 is common to all individuals. Estimation of 13, the vector of model parameters (assumed the same for all individuals), was accomplished by ordinary nonlinear LS based on (13) , "pooling" the data from all individuals. This is referred to as the "naive pooled data" method [7, 8] , since it ignores variation across individuals, Estimates of 13 obtained by this method can be very biased or imprecise [8] , and no assessment of inter-individual variability is possible. This method is not recommended [8] .
The nonlinear mixed effects model (12) is complex, since, in order to account for the two sources of variation, two random components, Zi and fi, are required. The random component zi appears in the model through the nonlinear functions hand f; thus, the effect of inter-individual variation on response measurements is complicated. Standard statistical methodology such as maximum likelihood (ML) estimation or LS is predicated on the ability to specify a distributional model for a response vector Yi. In this situation, because of the complex way in which Zi appears in the model, it is not possible to write down a distribution for yi, even if it is assumed that both Zi and fi are normally distributed. Thus, standard techniques may be difficult to implement. As a result, many of the methods that have been proposed for analysis of (12) are based on approximations which allow a distribution to be specified for Yi'
We now review some methods for estimation of " E, f3i, (7, and 9 for the nonlinear mixed effects model (12) that have been suggested in the literature. The methods we describe represent only some of procedures that have been proposed, and references to other methods are given.
Methods based on individual estimates
One approach to an approximation based on (12) is based on the ability to construct, for each individual, estimates f3i for f3i. These estimates form the basis for estimation of " E, (7, 9 and, in some cases, improved estimates for f3i. Intuitively, for this idea to be successful, sufficient data must be available on each individual for suitable f3i to be obtained. These methods are referred to as two-stage methods in the pharmacokinetics literature [7, 8, 12] since the idea consists of two stages: construction of f3i and subsequent estimation of other parameters.
The standard two-stage (STS) method [for example, 12] treats estimates f3i as if they were the true f3i' In the simplest case of (5), estimates for , and E would be constructed as (14) the sample mean and covarIance of , and E, respectively. Although simple, these estimators take no account of the uncertainty associated with estimation of f3i by 13:-The result is that the estimator for E can be very biased and imprecise. Furthermore, no attempt to improve on f3i by taking advantage of all available information is made.
These estimators are generally regarded as undesirable [4, 7, 8, 12 ].
The problems with STS estimation point out the need to take estimation error for f3i 0" o· 11 into account. Several methods to do this have been proposed [7, 8, 12, 13] ; we describe explicitly one such method, referred to in [12] as the global two-stage (GTS) method.
The method is given in terms of a linear inter-individual regression model as in (7) .
An assessment of the uncertainty of estimation in 13; may be obtained by appealing to large sample theory for nonlinear regression, as described in [3, sec. 3.2] . The theory states that, for large numbers of observations (in our case, large mi)' the sampling distribution of an estimator 13: is p-variate normal with mean l3i and some covariance matrix Vi' say, where the form of Vi is determined by the nature of f and 13: and depends on l3i. In practice, Vi is estimated by replacing parameters by estimates where they appear; henceforth, assume that Vi refers to such an estimate. If this theory is relevant, we have that, given l3i, 13 : is approximately normally distributed with mean l3i and covariance Vi' write 13: Il3i '" N(l3i, Vi). If we are further willing to assume that l3i is normally distributed with mean W(Y and covariance E, as suggested by (7) for normal Zi, then it follows that 13: '" N(W(y, Vi +E). This argument thus leads to a distributional assumption about 13:, suggesting that standard approaches to estimation of I and E may be used, treating the 13; as "data." The GTS method estimates I and E by ML estimation based on this normal distribution and is implemented by a two-step iterative algorithm [1, 12] which produces as a byproduct "refined" estimates of l3i that make use of information from all individuals. The algorithm may be started by using initial values for I and E from (14) . At iteration (k+1):
(1) Produce refined estimates of l3i: (2) Obtain updated estimates of I and E:
.=1
Iteration continues until the algorithm converges to final estimates 1', t, and Pi. Note that the "refined" estimates in (15) have the form of a "weighted average" of the individual estimate P: obtained from the data for individual i only and Wi1', the estimate of l3i predicated on (7) using data from all individuals. These estimates are in fact empirical Bayes estimates for l3i; that is,~i is the mean of the distribution of l3i given the data {Yij}, where '1 and~have been replaced by the current estimates [12] . is not straightforward to use these methods when one of the components of l3 i is taken to remain constant across individuals, as in the pharmacokinetic example (10).
For any two-stage method, the quality of the estimates of '1 and~will depend on the quality of the estimates 13:. If intra-individual variance is not constant but varies according to the function g with response level, using ordinary LS estimates for 13: will be undesirable, because LS estimates will be inefficient relative to estimates based on weighted least squares (WLS) [3] . The weighting scheme to be used will depend on what is known about the function g. As is frequently the case, one may be able to specify a function g which describes the pattern of variation, but the value of 9
providing a full characterization is unknown and must be estimated from the data [3] .
If it is realistic to assume a common pattern of variation for all individuals, as in (12) , it makes sense to use the data from all individuals to estimate 9 (and u) rather than to estimate separate values for each individual.
This idea is the basis for the following proposal for obtaining 13: advocated in [4] . We first review estimation for data from a single individual. As described in [3] , 
13 and form estimated weights w~~) = l/g 2 { f(Xii' fJ:(k»), e(k)}. 3 . Obtain the GLS estimator of fJi by WLS with weights w~~). Set k = k+ 1, let fJ: (k) be this GLS estimator, and return to step 2.
The objective functions for estimation of ((1,8) in step 2 are motivated in [3, 4] . The scheme may be iterated a fixed number of times or until convergence, see [3] .
In [4] , the GLS algorithm is extended to allow estimation of (1 and (J based on data from all individuals: 
For each individual i, obtain the GLS estimator of fJi by WLS with weights w~~).
Set k = k+ 1, let fJ:(k), i = 1, ... , n be these GLS estimators, and return to step 2.
In step 2, information from all individuals on the (common) intra-individual variance structure is used to estimate ((1,8) by pooling information across individuals. Since the objective function is simply the sum of the objective functions for all individuals, minimization is no more difficult than for data from a single individual only. See [3] and [4] for details on implementation with standard software. As in the case of individual data, this scheme is iterated a fixed number of times or until convergence.
The final estimates fJi from this scheme are proposed in [4] as input to one of the procedures such as GTS for estimation of I and~. These fJi are to be preferred to those based on a separate estimate for 8 for each individual because they are likely to be more precise, since they are based on a weighting scheme that takes advantage of the information from all individuals through the "pooled" estimation of (1 and 8.
To summarize, the procedure is: (1) Obtain fJi by the GLS algorithm based on pooled estimation of ((1, (J), and use these estimates to form Vi; (2) Use fJi and Vi as input to a scheme such as GTS to estimate (I,~) and obtain refined estimates of fJi if desired. These "pooled two-stage" (PTS) methods may be used when sufficient data are available to obtain estimates fJi from each individual.
Methods based on linearization
The other mam class of approaches to estimation m the nonlinear mixed effects 14 model is based on linearization of the model (12) by a Taylor senes III the random effects Zi' This idea was first advocated by Beal and Sheiner [7, 8] . Under the assumption that Zi'" (0, E) and fi'" (0, 1 m .), they proposed that the Taylor series be Sheiner to obtain estimates of (" E, (]", 8) by maximizing in these parameters the normal likelihood for the data vectors Yi, i = 1, ... , n, corresponding to these assumptions. In the pharmacokinetics literature, this procedure is referred to as the "First-Order" method, and the estimation scheme corresponding to normal ML is referred to as Extended Least Squares (ELS) [7, 8, 9] . The method is implemented in the software package NONMEM [14] ; the reader is referred to this documentation for computational details. The individual Pi may be estimated by an empirical Bayes approach as well [14] . NONMEM is widely used in the analysis of population pharmacokinetic data. For some problems, this approach can be computationally intensive.
Recently, Vonesh and Carter [5] have proposed an alternative to the ELS method which is also based on the linearization (18) but is computationally simpler. In [1] , their method has been modified to incorporate a variance function g and estimation of fJ. The procedure is a four-step iterative algorithm in the spirit of GLS. The second step is based on the idea that, if , were known in (18), [Yi -fi{h(W i ", On] = Di(W i ", 0) Zi + (] " Gi{h(W i ", 0), fJ} fi is a weighted linear "regression model" for individual i with "regression parameter" Zi' "design matrix" Di(W i ", 0), and . "covariance matrix" (]"2 GHh(W i ", 0), 8}.
Step 1.
Let k = 0, and obtain the ordinary LS estimator 1'(0) by minimizing in , ' and let G;
Step 3.
Let Szz = (n-l)-I f: (z~k)_z)(z~k)_Z)T ,z = n-I f: z~k), and estimate~by i=I i=I
Step 4.
. . .. . Maximization of these objective functions in step 2(ii) can be accomplished using standard software, see [1, 3, 4] .
The covariance matrix of 1'(k+I) obtained at the end of the Step 4 can be estimated by (21) where
and
may be used when information from each individual is sparse as long as mi~M.
Lindstrom and Bates [11] suggest that the approximation based on Zi ==°can be improved and propose a computational method based on a Taylor series of (12) 
To base estimation of (/" E, 0", 8) on this approximation, it is necessary to have available a value for zi. Lindstrom and Bates propose an iterative scheme in which an estimate of Zi is obtained at each iteration. This estimate is inserted in the expressions in (22) , and updated estimates of (" E, 0", 8) and Zi are obtained. The iterative computation is fairly complex; we only summarize the basic idea. At iteration (k+1): ' and z~k), obtain updated estimates z~k+I) of Zi: maximize the likelihood for Zi given the data Yij under the assumption that the Zi and €i are normal, obtaining the estimates
where ' 8(k+l) maxImIZing In b,~,cr,8) the normal likelihood for the data vectors Yi' i = 1, ... , n, with means and covariance matrices f .{h(W. 'V zA(k+l))} _ n A .zA(k+l) n A~n AT+ 2G2{h(W A A(k+l)) Ll}
,u , respectively.
We refer the reader to [11] for full details and computational strategies. In the above, we have modified the Lindstrom and Bates proposal for nonlinear h and to incorporate estimation of 8 in a variance function depending on f3 i . At the end of (2), estimates of the individual f3i may be obtained as~~k+l) = h(Wi,1'(k+l),z~k+l)).
Other methods
As pointed out in Section 4.1, the major classes of methods that we have discussed are based on approximations or individual estimates because the complexity of the model (12) makes the use of standard methodology difficult. This is because it is not possible in general to specify a distribution for the data vectors Yi, even with distributional assumptions for Zi and fi' We now examine this problem more closely. If we were to assume, for example, that the fi are normally distributed, this would imply that, given f3i (and hence, given Zi), Yi are normally distributed with mean vector f i (f3i) and covariance matrix cr 2 GHf3i' 8). Writing </>(a, B) to be the normal density with mean vector a and covariance matrix B, if zi is assumed to be distributed with some density t/J( . I~) depending on~, the exact likelihood for the response vector yi is (23) the likelihood for the entire data set would be the product of n such integrals, one for each individual. Even if t/J is the normal density </>(0,~), this integral is not analytically tractable for general functions f, g, and h.
Recently, methods have been proposed which, under various assumptions, represent attempts to perform this integration in order to estimate the parameters. A full description of these methods is beyond the scope of our discussion; we provide only a brief summary and references.
Gelfand, et al. [15] take a full Bayesian approach to the nonlinear mixed effects model. They assume that Zi and fi are normally distributed random vectors and place prior distributions on the parameters "~, and cr. (They do not consider estimation of parameters () in a variance function g, although their idea can be extended to this case.) In this framework, several integrations, including that in (23), need to be performed. A computationally intensive Gibbs sampling algorithm is advocated to perform these integrations; a description of this approach and specific details are given in [15] .
Mallet et al. [16] note that the assumption that Zi are normally distributed may be questionable in population pharmacokinetic analysis. They propose estimation of the density of Zi, "p, in (23) by a nonparametric method. The parameters, and u are then estimated by integrating (23) with this estimate inserted for"p. Since the estimate for "p consists of a finite number of points, the integral becomes a sum, which may be evaluated easily. See [16] for a full exposition.
Davidian and Gallant [17] also eschew the standard normality assumption for "p.
They propose a different nonparametric estimator for "p which is not a finite number of points but rather is a smooth function of z. By using numerical integration, they compute the integral (23) and estimate "p, "~, u, and 9 simultaneously. The form of the estimator for "p includes 4>, the normal density, as a special case.
The methods in this section can involve fairly substantial computational costs. For all methods, including those discussed in Sections 4.2 and 4.3, very little is known about relative performance. This issue is a basis for current research.
EXAMPLES REVISITED
Bioassay of relaxin by RIA
Calibration of unknown samples for the current run of a cell-based bioassay such as that for relaxin is always based on the standard curve for that run. As noted in Section 2.1, accurate characterization of intra-assay variability in the response is essential for assessing the precision of calibration. We now illustrate how this issue may be addressed for the relaxin bioassay within the nonlinear mixed effects model framework.
Variability in assay responses is an increasing function of response level, and a standard model for characterizing this feature is the power of the mean variance function [2] . That is, for run i,
for some power 9. It is commonly acknowledged that for many assays, usual default choices for this power, such as 9 = 0.5 or 1.0, may be inappropriate [18] . Thus, one objective of an analysis is to determine an appropriate value for 9 for the ith run A standard technique for evaluating intra-assay precision associated with calibration of an unknown sample for a given run is to construct a precision profile [19] . 20 Under these assumptions, Table 4 displays the results of several fits to the relaxin data, both separately by assay run and pooled across assay runs. Because results were very similar for both objective functions in (17) for individual and pooled estimation, we report results for PL only. Although individual estimates of () are fairly similar across runs, the value for run 9 seems somewhat aberrant. This is probably attibutable to the difficulty in estimating variance parameters mentioned above. The pooled estimate for () based on data from all nine runs indicates that a constant CV model for intra-assay variance would be a reasonable choice for routine use.
In Figure 5 , a precision profile for a single replicate of an unknown sample is constructed based on each fit for run 9. The profile based on the LS fit is inappropriate, since it takes no account of the nature of intra-assay variance. The profiles based on individual and pooled GLS fits differ appreciably over a large range of concentrations, reflecting the sensitivity of calibration inference to the method used to characterize intra-assay variability. If the model assumptions are correct, then the profile based on the pooled GLS fit will provide the most accurate assessment of precision.
More extensive analysis of this example and further discussion of issues arising in calibration, including the use of refined estimates of f3i from GTS as a basis for calibration, is given in [18] .
Water transport kinetics of high flux hemodialyzers
An objective of the dialyzer study was to compare the kinetic properties of dialyzers operated at the two flow rates. We now address this question in the context of the nonlinear mixed model framework, assuming the kinetic model fin (3) throughout.
In a preliminary analysis, Vonesh and Carter [5] where '11 = [ '11" '12" '131] T is the vector of "typical" kinetic parameters for a dialyzer operated at flow rate 1 = 200 or 300 ml/min, and Zi = [Zil' Zi2]T is the random vector describing how the first two parameters, maximum ultrafiltration rate and permeability transport rate, vary in both flow rate populations. This model may be written as f3i = Wi'1 + Riz i , where '1 = bi'oo,'1ioo]T (6x1), Wi is defined in (8) , and R i is the (3x2) matrix whose columns are the first two columns of 1 3 • From Figure 3 , intra-dialyzer variability is an increasing function of ultrafiltration level. To accommodate this feature, we assume that intra-dialyzer variance follows the power of the mean model (24). In their analysis, Vonesh and Carter [5] assumed constant intra-dialyzer variance.
The two-stage methods in Section 4.2 do not allow for the possibility that some components of Pi are fixed; the methods based on linearization in Section 4.3 do accommodate such a model. We thus used the four-step GLS algorithm given in Standard errors for 1 may be obtained as the square roots of the estimated covariance matrix nin (21) . For the assumed model, nis a (6 X 6) block diagonal matrix with degrees of freedom, this is highly significant (p<0.0001), suggesting that, overall, kinetic properties of dialyzers operated at 200 ml/min differ from those of dialyzers operated at 300 ml/min. Inspection of the estimate ..y indicates that this result is largely due to differences in the first two components of 1200 and 1300' maximum attainable ultrafiltration rate and hydraulic permeability transport rate, for the two flow rates. This is the same qualitative result obtained in [5] assuming constant intra-dialyzer varIance. Although our conclusion is the same, the knowledge that intra-dialyzer variance increases with mean response is useful for further study of the process.
Evidence suggesting that incorrect specification of the intra-individual variance function can produce biased, less reliable estimates of 1 and L: is given in [1, 4] .
Pharmacokinetics of cefamandole
One objective of a pilot pharmacokinetic study is to characterize intra-subject variation, which is typically an increasing function of plasma level. A second objective is to determine a suitable kinetic model and to obtain preliminary estimates of the values of the pharmacokinetic parameters. All of this information is used in subsequent design and analysis of pharmacokinetic studies in a patient population. These objectives may be addressed within the nonlinear mixed effects model framework.
From Section 2.3, the biexponential model is a suitable representation of the kinetics of cefamandole at time x. This model is often written in the form (25) 23 in order to ensure positivity of the parameter estimates [20] . We adopt this model for f in our analysis of the cefamandole data.
A standard model for intra-subject variance in pharmacokinetic applications is the power of the mean model (24). As discussed by [9] , for pharmacokinetic data, usual default values for {} are often inappropriate, so it is necessary to estimate the power parameter {} from the data. Since the same assay is used to process blood samples from all subjects, it is not unreasonable to expect a similar pattern of intra-subject variability for all subjects. Thus, we assume that the intra-subject variance function g is given by (24) with unknown power {}, common to all individuals, to be estimated.
Because no information on individual attributes is available, we take the interindividual regression model h to be where 13i is the (4 x 1) vector of parameters in the order given in (25) for the ith subject.
Within this framework, , is the vector of "typical" pharmacokinetic parameters.
Estimates of , and E, the covariance matrix of Zi' provide the required preliminary information on kinetics as well as a sense of how kinetic properties vary. Variability in the kinetic parameters is usually expressed as a coefficient of variation, that is, the square root of the appropriate diagonal element of t (the estimate of standard deviation for the kinetic parameter) divided by the corresponding component of 1', times 100%.
Under these assumptions, we used the GLS algorithm of Section 4.2 where the data are pooled across subjects to estimate (u, (}) using the PL objective function. Final estimates 13: and corresponding estimated covariance matrices Vi from this procedure, were input to the GTS algorithm to estimate, and E. Refined estimates~i of the individual parameters 13i were also obtained. Results are summarized in Table 5 (a).
Refined estimates of the elements of 13i differ from the pooled GLS estimates; this is due to the well-known phenomenon that empirical Bayes estimates borrow information across the sample to "shrink" individual estimates toward the mean parameter value.
The four-step GLS algorit~m in Section 4.3 was also used to estimate (" E, u, (}) and obtain individual estimates~i = l' + Zi' where l' and zi are the final estimates of, and Zi' The PL objective function was used for estimation of (u,{}). Results after 3 iterations of the algorithm are given in Table 5 (b). Estimated CVs for the parameters based on both analyses suggest that rate constants (and hence, half life) vary appreciably among subjects, although this result is to be interpreted with care, as we now discuss. One would hope that the two different estimation methods would produce comparable results, and they do yield similar estimates for " u, and fJ. The most striking difference between the two analyses is that the estimates of the covariance matrix E differ appreciably. This disagreement reflects the idea that estimation of variation in the population is unlikely to be very reliable when based on such a small sample from the population (six subjects). In general, estimation of E should not be attempted unless the number of individuals sampled (n) is large. The quality of estimates of I, u, and (J are not as adversely affected by small n, in our experience.
CONCLUSION
The nonlinear mixed effects model is a useful and flexible framework for the analysis of repeated measurement data. In this tutorial, we have reviewed several approaches to estimation and inference within this framework and illustrated these with data sets from a range of areas of application. The examples illustrate the types of analyses that are possible as well as the care that must be taken in interpreting the results. In particular, the cefamandole example highlights the fact that estimation of variation in the population of individuals can be unreliable when the number of individuals sampled is small. Research is currently under way to investigate this and other issues.
The cefamandole example illustrates the analysis of pharmacokinetic data from a small, controlled pilot study. Clinical data from a patient population usually consist of only a few plasma concentration measurements on each of a large number of subjects along with information on patient attributes such as physical characteristics and disease status. The analysis of these data is often complex, and the improvement of existing techniques as well as the development of new procedures is an area of current research [21, 22] .
An extensive bibliography of references on population pharmacokinetic analyses is given in [23] . 
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Figure Captions
Concentration-response data for two runs of the relaxin bioassay.
Ultrafiltration rate data for twenty high flux hemodialyzers operated at two blood flow rates. Each symbol represents data for a different dialyzer.
Standardized LS residuals versus predicted response for the dialyzer data. Each symbol represents data for a different dialyzer.
Cefamandole plasma level-time profiles for six subjects. Each symbol represents data for a different subject.
Precision profiles for three different fits to run 9 of the relaxin bioassay: dotted line, LS based on individual data; dashed line, GLS-PL based on individual data; solid line, GLS-PL based on pooled data. <: 
